Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AprilBio Out-Licenses Rights for IL-18 Candidate to California’s Evommune

publication date: Jun 24, 2024

Korea’s AprilBio out-licensed worldwide rights for its IL-18 targeted fusion protein to Evommune, a Palo Alto biopharma focused on chronic inflammatory diseases. APB-R3 (now known as EVO301) is a long-acting injectable fusion protein aimed at neutralizing the signal pathway of IL-18 to regulate inflammation. AprilBio said the fusion protein showed good safety and tolerability, favorable pharmacokinetics and target engagement in its Phase I trial. Evommune is developing a portfolio of three immune therapies, including another candidate that targets the IL-18 pathway for atopic dermatitis. Financial details of the agreement were not disclosed. More details....

Stock Symbol: (Kosdaq: 397030)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here